LEBWOHL, M.; KIRCIK, L. .; MOORE, A.; STEIN GOLD, L.; DEL ROSSO, J.; DRAELOS, Z.; GOODERHAM, M.; GREEN, L.; HERBERT, A.; PAPP, K.; BAGEL, J. .; BHATIA, N.; FERRIS, L.; JONES, T. .; KEMPERS, S.; PARISER, D.; YAMAUCHI, P.; ZIRWAS, M.; FENG, A. .; BURNETT, P.; HIGHAM, R.; BERK, D. Once-Daily Roflumilast Cream 0.3%, a Potent Phosphodiesterase-4 Inhibitor, Provided Safe and Effective Treatment of Psoriasis in the DERMIS-1 and DERMIS-2 Phase 3 Trials. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 5, n. 6, p. s42, 2021. DOI: 10.25251/skin.5.supp.42. Disponível em: https://www.jofskin.org/index.php/skin/article/view/1393. Acesso em: 22 may. 2022.